Abstract
13 patients (pts) with HUS were studied.All were treated in the last 2.5 years.5 were treated with ASA (1 pt.,6mg/kg/day for 28 days),or with ASA (6 to 16 mg/kg/day)and D(2 to 5 mg/kg/day) for 9 to 49 days and 8 received supportive therapy only.There were no significant differences between the 2 groups in age,sex, prevalence of extrarenal manifestations,lowest hematocrit and platelet count,number of transfusions needed,duration of thrombocytopenia or number of pts requiring dialysis.The treated pts were oligurlc and required dialysis for a shorter period of time than the untreated pts(days with urinary output<200ml/m2/day:1.6 ±0.89,range 1-3 compared to 5.63±5.83,range 0-19;days between admission and last dialysis 2.15±2.47,range 0-6 compared to 4.8± 8.76,range 0-26). The differences however were not significant. After periods of follow-up ranging from 3.5 to 18.25 months,all pts had grown normally and had GFR's ranging from 90 to 196ml/min/1.73m2. None had hematuria.One of the untreated pts had mild proteinuria (7mg/m2/hr on overnight specimen).
We conclude that ASA and D do not alter the long term prognosis of HUS.The shorter duration of oliguria and of dependence on dialysis in our treated pts,though not statistically significant, suggests a larger study is warranted.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gauthier, B., Schoeneman, M., Shende, A. et al. 1069 HEMOLYTIC UREMIC SYNDROME(HUS). COMPARISON OF SUPPORTIVE CARE AND ASPIRIN(ASA) AND DIPYRIDAMOLE(D)THERAPY. Pediatr Res 12 (Suppl 4), 542 (1978). https://doi.org/10.1203/00006450-197804001-01075
Issue Date:
DOI: https://doi.org/10.1203/00006450-197804001-01075